Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab Plus Chemotherapy in Early or Locally Advanced TNBC
NCT06977542Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Jun 2025
- Primary completion
- Jan 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 2 trial of ivonescimab in triple-negative breast cancer (TNBC), sponsored by Fudan University. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06977542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06977542.